Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...

Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

HealthDay News — For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC), according to a review published online ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...